Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-dose furmonertinib for EGFR-mutant NSCLC with brain metastases
ChiCTR2200057048Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of furmonertinib in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by West China Hospital of Sichuan University. Primary endpoints: Intracranial objective response rate, Intracranial progression-free survival and 2 more. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on ChiCTR2200057048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057048.